MedTrace Logo

Effects of Lubiprostone on Gastric Function in Patients With Chronic Idiopathic Constipation

NCT01460225 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-07-13

Study results available
· View outcomes & findings →

Summary

This prospective study is designed to evaluate how lubiprostone may affect gastric motor and sensory function.

Conditions

  • Chronic Idiopathic Constipation

Interventions

DRUG

lubiprostone

24 micrograms twice daily for 1 week

Sponsors & Collaborators

  • Takeda Pharmaceuticals North America, Inc.

    collaborator INDUSTRY

  • Dartmouth-Hitchcock Medical Center

    lead OTHER

Study Design

Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-12-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01460225 on ClinicalTrials.gov